Achieved 66% annual revenue growth driven by Auvelity's rapid uptake, which surpassed $500,000,000 in net sales in its third full year of launch. Attributed Auvelity's outperformance to its distinct clinical profile and fast onset of action, allowing it to grow 42% year-over-year while the broader antidepressant market remained flat. Expanded the primary care prescriber base for Auvelity, which now represents approximately one-third of all prescribers and is the fastest-growing segment. Initiated a ...